Cytogen, Inc. (KOSDAQ:217330)
South Korea · Delayed Price · Currency is KRW 3,945.00
-95.00 (-2.35%)
At close: Apr 9, 2026
Cytogen Revenue
In the year 2025, Cytogen had annual revenue of 26.05B KRW with 138.80% growth. Cytogen had revenue of 6.55B in the quarter ending December 31, 2025, with 17.21% growth.
Revenue
26.05B
Revenue Growth
+138.80%
P/S Ratio
3.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
93.09B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 26.05B | 15.14B | 138.80% |
| Dec 31, 2024 | 10.91B | 7.73B | 242.63% |
| Dec 31, 2023 | 3.18B | 2.42B | 318.57% |
| Dec 31, 2022 | 760.78M | 412.93M | 118.71% |
| Dec 31, 2021 | 347.85M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Green Cross Medical Science | 108.41B |
| Seoulin Bioscience | 77.09B |
| Dx & Vx | 29.36B |
| Protia | 15.12B |
| HLB Panagene | 15.05B |
| 3billion | 11.71B |
| GENINUS | 10.48B |
| Median Diagnostics | 7.86B |